Effect of Exercise and Weight Loss on Cardiovascular Health

Obesity Clinical Trial

— Heart Health  

Official title:

Effect of Exercise and Weight Loss on Cardiovascular Health

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01500356
• Other study ID #: HL103646
• Status: Completed
• Phase: N/A
• First received: December 22, 2011
• Last updated: July 24, 2017
• Start date: December 13, 2011
• Est. completion date: June 30, 2016

Study information

• Verified date: July 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary aim of this study is to examine the effect of the consensus public health recommended level of physical activity [moderate physical activity (MOD-PA) = 150 min/wk] versus a higher dose of physical activity [high physical activity (HIGH-PA) = 250 min/wk] in the context of a comprehensive behavioral weight loss program that a includes a reduction in energy intake measures of cardiovascular function using cardiac MRI and biomarkers of vascular disease risk. Each of these exercise doses will be compared independently to a Diet Only group intervention on the proposed primary and secondary outcomes, with MOD-PA also compared to HIGH-PA. This study involves the recruitment of 390 overweight and obese adults who will be randomly assigned to one of the above conditions (Diet Only, MOD-PA, HIGH-PA) for a period of 12 months. The primary outcome is LVM measured by cardiac MRI. Secondary outcomes include additional cardiac MRI measures (aortic pulse wave velocity, end diastolic volume, aortic distensibility), inflammatory markers (CRP and TNFα) and selected adipocytokines (adiponectin) as biomarkers of risk related to vascular outcomes, body weight, body composition, and cardiorespiratory fitness, and traditional CVD risk factors (lipids, glucose, insulin, blood pressure). Additional secondary analyses will allow for examination of the effects of physical activity independent of weight change on the primary and secondary outcomes.

Description:

Current estimates indicate that in excess of 65 percent of adults in the United States are overweight (BMI >25.0 kg/m2) with at least 30 percent of adults classified as obese (BMI >30 kg/m2). Overweight and obesity have been linked to numerous chronic conditions including cardiovascular disease. The application of cardiac MRI (CMRI) allows for direct measurement of the cardiac structure, and left ventricular mass (LVM) assessed by CMRI has been shown to be predictive of cardiovascular disease. Recent studies have shown that LVM is decreased with weight loss; however, there is a lack of information on the added benefit of physical activity to weight loss on these direct measures of cardiovascular structure and function. Thus, consistent with PA-09-243, this study will examine the effect of two recommended doses of physical activity combined with a dietary intervention on changes in the proposed outcomes of cardiovascular disease risk in overweight adults.

The primary aim of this study is to examine the effect of the consensus public health recommended level of physical activity [moderate physical activity (MOD-PA) = 150 min/wk] versus a higher dose of physical activity [high physical activity (HIGH-PA) = 250 min/wk] in the context of a comprehensive behavioral weight loss program that a includes a reduction in energy intake measures of cardiovascular function using cardiac MRI and biomarkers of vascular disease risk. Each of these exercise doses will be compared independently to a Diet Only group intervention on the proposed primary and secondary outcomes, with MOD-PA also compared to HIGH-PA. This study involves the recruitment of 390 overweight and obese adults who will be randomly assigned to one of the above conditions (Diet Only, MOD-PA, HIGH-PA) for a period of 12 months. The primary outcome is LVM measured by cardiac MRI. Secondary outcomes include additional cardiac MRI measures (aortic pulse wave velocity, end diastolic volume, aortic distensibility), inflammatory markers (CRP and TNFα) and selected adipocytokines (adiponectin) as biomarkers of risk related to vascular outcomes, body weight, body composition, and cardiorespiratory fitness, and traditional CVD risk factors (lipids, glucose, insulin, blood pressure). Additional secondary analyses will allow for examination of the effects of physical activity independent of weight change on the primary and secondary outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 383
• Est. completion date: June 30, 2016
• Est. primary completion date: June 30, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• 18-55 years of age.

• Body mass index (BMI) between 25.0 to <40.0 kg/m2.

• Ability to provide informed consent prior to participation in this study.

Exclusion Criteria:

• Females who are currently pregnant or breastfeeding, or reporting that she is planning a pregnancy within the next 12 months.

• History of bariatric surgery.

• Report current medical condition or treatment for a medical condition that could affect body weight. These may include the following: cancer (Note: Persons previously diagnosed with non-melanoma skin cancers, those successfully treated for cancer who have remained disease-free for five years or more would be eligible for participation in this study); diabetes mellitus; hyperthyroidism; inadequately controlled hypothyroidism; chronic renal insufficiency; chronic liver disease; gastrointestinal disorders including ulcerative colitis, Crohn's disease, or malabsorption syndromes; etc.

• Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e. recent or recurrent DVT).

• Resting systolic blood pressure of >160 mmHg or resting diastolic blood pressure of >100 mmHg.

• Eating disorders that would contraindicate weight loss or physical activity.

• Alcohol or substance abuse.

• Currently treated for psychological issues (i.e., depression, bipolar disorder, etc), taking psychotropic medications within the previous 12 months, or hospitalized for depression within the previous 5 years.

• Report exercise on >3 days per week for >20 minutes per day over the past 3 months. (NOTE: It is important that individuals are sedentary when entering this study to allow for maximal effect of the intervention.)

• Report weight loss of >5% or participating in a weight reduction diet in the past 3 months.

• Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance to at least 80 percent of the scheduled intervention sessions and all of the scheduled assessments.

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Obesity
• Weight Loss

Intervention

Behavioral:
• Behavioral weight loss intervention
Weight loss intervention that focuses on reducing energy intake.
• Diet Plus Moderate Exercise
Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
• Diet Plus High Exercise
Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.

Locations

Country	Name	City	State
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Left ventricular mass assessed using cardiac MRI	Left ventricular mass will be assessed using cardiac MRI	Baseline (0 months) and 12 months
Secondary	Change in end-diastolic volume assessed using cardiac MRI	Assessed using cardiac MRI	baseline (0 months) and 12 months
Secondary	Change in cardiorespiratory fitness	Measured using a graded exercise test	baseline (0 months) 6 months, and 12 months
Secondary	Change in blood levels of C-Reactive Protein (CRP)	Assessed from a fasting blood sample	baseline (0 months), 6 months, and 12 months
Secondary	Change in body weight		baseline (0 months), 6 months, and 12 months
Secondary	Change in body composition	Measured using dual-energy x-ray absorptiometry (DXA)	baseline (0 months), 6 months, and 12 months
Secondary	Change in regional adiposity	Measured using anthromometry that includes girth measures of the waist and hip	baseline (0 months), 6 months, 12 months
Secondary	Change in physical activity	Measured using both a wearable device and by questionnaire	baseline (0 months), 6 months, 12 months
Secondary	Change in energy intake	Assessed using a questionnaire	baseline (0 months), 6 months, 12 months
Secondary	Change in traditional CVD risk factors (lipids, glucose, insulin)	Measured from a fasting blood sample	baseline (0 months), 6 months, 12 months
Secondary	Change in resting blood pressure		baseline (0 months), 6 months, 12 months